Daiichi Sankyo Company, Limited ( OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT ...

AstraZeneca and Daiichi Sankyo are challenging Gilead Sciences for dominance in one of the toughest-to-treat breast cancers in a race for patients — and profits.

Enhertu can help patients with breast cancer when given earlier in the disease, according to data presented at the ESMO ...

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

Meanwhile, AstraZeneca’s Enhertu partner Daiichi arrived at ESMO armed with its own ADC data for the cadherin-6-targeting ...

AstraZeneca Plc and Daiichi Sankyo Co. are challenging Gilead Sciences Inc. for dominance in one of the toughest-to-treat breast cancers, with new data from Europe’s biggest oncology meeting signaling ...

Europe’s leading cancer conference may be swimming in antibody-drug conjugate data, but AstraZeneca remains convinced that ...

Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis.

In light of new data at ESMO, researchers debated whether HER2-targeted tyrosine kinase inhibitors or antibody-drug conjugates might be better as initial treatment.

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by ...